Current Report Filing (8-k)
June 22 2020 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 22, 2020
ATYR PHARMA, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-37378
|
|
20-3435077
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
3545 John Hopkins Court, Suite #250
San Diego
|
|
|
|
92121
|
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (858) 731-8389
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
LIFE
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD Disclosure.
aTyr Pharma, Inc. (the “Company”) is participating at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II which is being held on June 22 - 24, 2020. The Company will present a poster entitled “Domain-Specific Antibodies to Neuropilin-2 Implicate VEGF-C and Not Semaphorin 3F in Breast Cancer Stem Cell Function” via a pre-recorded audio recording on the AACR website. The poster presentation has been posted on the Company’s website and is attached hereto as Exhibit 99.1.
The information under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ATYR PHARMA, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Jill M. Broadfoot
|
|
|
|
Jill M. Broadfoot
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|
Date: June 22, 2020
|
|
|
3
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024
